Low Dose Thalidomide in Patients with Relapsed or Refractory Multiple Myeloma

References

• Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F. and Dammacco, F. (1999) "Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma", Blood 93, 3064–3073.
   PubMed Web of Science ®Google Scholar
• Singhal, S., Metha, J., Desikan, R., Ayers, D., Robertson, P., Eddlemon, P., Munshi, N., Anaissie, E.,Wilson, C., Dhodapkar, M., Zeldis, J. and Barlogie, B. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", New England Journal of Medicine 341, 1565–1571.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J. and Munshi, N. (2001) "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients", Blood 98, 492–494.
   PubMed Web of Science ®Google Scholar
• Rajkumar, V., Fonseca, R., Dispenzieri, A., Lacy, M., Lust, J., Witzig, T., Kyle, R., Gertz, M. and Greipp, P. (2000) "Thalidomide in the treatment of relapsed multiple myeloma", Mayo Clinic Proceedings 75, 897–901.
   PubMed Web of Science ®Google Scholar
• Hus, M., Dmoszynska, A. and Soroka-Wojtaszko, M. (2001) "Thalidomide treatment of resistant or relapsed multiple myeloma patients", Haematologica 86, 404–408.
   PubMed Web of Science ®Google Scholar
• Noopur, R. and Anderson, K. (1999) "Thalidomide: a revival story", New England Journal of Medicine 341, 1606–1609.
   PubMed Web of Science ®Google Scholar
• Worel, N., Greinix, H., Ackermann, J., Kaufmann, H., Urbauer, E., Ho�cker, P., Gisslinger, H., Lechner, K., Kalhs, P. and Drach, J. (2001) "Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after highdose therapy in patients with multiple myeloma", Annals of Hematology 80, 345–348.
   PubMed Web of Science ®Google Scholar
• Weber, D., Rankin, K., Gavino, M., Delasalle, K. and Alexanian, R. (2003) "Thalidomide alone or with dexamethasone for previously untreated multiple myeloma", Journal of Clinical Oncology 21, 16–19.
   PubMed Web of Science ®Google Scholar
• Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P. and Crowley, J. (2000) "Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities", Blood 95, 4008–4010.
   PubMed Web of Science ®Google Scholar
• Palumbo, A., Giaccone, L. and Bertola, A. (2001) "Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma", Haematologica 86, 399–403.
   PubMed Web of Science ®Google Scholar
• Rajkumar, S.V., Hayman, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Greipp, P.R., Geyer, S., Iturria, N., Fonseca, R., Lust, J.A., Kyle, R.A. and Witzig, T.E. (2002) "Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma", Journal of Clinical Oncology 20, 4319–4323.
   PubMed Web of Science ®Google Scholar
• Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. and Anderson, K.C. (2000) "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy", Blood 96, 2943–2950.
   PubMed Web of Science ®Google Scholar
• Neben, K., Moehler, T., Kraemer, A., Benner, A., Egerer, G., Ho, A. and Goldschmidt, H. (2001) "Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion", British Journal of Haematology 115, 605–608.
   PubMed Web of Science ®Google Scholar
• Mitsiades, N., Mitsiades, C., Poulaki, V., Chauhan, D., Richardsn, P.G., Hideshima, T., Munshi, N.C., Treon, S.P. and Anderson, K.C. (2002) "Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications", Blood 99, 4525–4530.
   PubMed Web of Science ®Google Scholar
• Klein, B. (1995) "Cytokine, cytokine receptors, transduction signals and oncogenes in human multiple myeloma", Seminars in Hematology 32, 4–19.
   PubMed Web of Science ®Google Scholar
• Kaufmann, H., Urbauer, E., Ackermann, J., Huber, H. and Drach, J. (2001) "Advances in the biology and therapeutic management of multiple myeloma", Annals of Hematology 80, 445–451.
   PubMed Web of Science ®Google Scholar
• Raje, N. and Anderson, K.C. (2002) "Thalidomide and immunomodulatory drugs as cancer therapy", Current Opinion in Oncology 14, 635–640.
   PubMed Web of Science ®Google Scholar
• Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Chauhan, D., Traeon, S.P., Gupta, D., Mitsiades, C., Mitsiades, N., Hayashi, T., Richardson, P.G., Schlossmann, R.L., Muller, G.W., Stirling, D.I. and Anderson, K.C. (2001) "Thalidomide and immunomodulatory derivates augment natural killer cell cytotoxicity in multiple myeloma", Blood 98, 210–216.
   PubMed Web of Science ®Google Scholar